Origin Energy 1Q21 Production

Nat Gas prices continue to rebound from the historic lows reached mid this year.

Origin share price remains under selling pressure but is likely to soon find buying support.

Origin’s September quarter revenue of A$374m was down 39% from the prior quarter. Lower prices were in part offset by higher production volumes.

CURE ETF

After recently taking profit in the CURE ETF, we again add the name back onto our watchlist and identify the range where we expect buying support to rebuild.

Buy $58.50 target.

Separate to the above opportunity, we see upside in the large-cap biotech stocks in the US. In particular, we like Abbvie, Biogen, Gilead, Johnson & Johnson, Merk, and Pfizer.

If you’d like to discuss setting up a US broking account with Investor Signals, please call me on 1300 614 002.